Patient-Reported Outcomes in Vitiligo: QoL Scales, Minimal Important Change, and Clinic Integration
Key Takeaways Why measure QoL? VASI captures extent, but not impact (stigma, avoidance, mood). PROMs close that gap. Core tools: […]
Key Takeaways Why measure QoL? VASI captures extent, but not impact (stigma, avoidance, mood). PROMs close that gap. Core tools: […]
Key Takeaways Face/neck first-line: topical calcineurin inhibitors (tacrolimus 0.03–0.1%) are preferred to avoid steroid atrophy. Generalized disease: NB-UVB 311 nm 2–3×/wk
Key Takeaways Why PROMs? Pigment changes affect visibility, stigma, and function. PROMs help prioritize sites (e.g., face/hands) and set goals
Key Takeaways Vitiligo imposes a clinically meaningful quality-of-life (QoL) burden; facial and visible-area involvement, rapid progression, and darker phototypes are
Key Takeaways Global point prevalence typically falls within ~0.5–2%, with heterogeneity by region and methodology. Childhood onset is common (≈30–50%